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AbstrACt
Objectives The objectives were to characterise the 
haematological profile of screen-detected chronic kidney 
disease (CKD) participants and to correlate the complete 
blood count measures with the commonly advocated 
kidney function estimators.
Methods The current cross-sectional study used data, 
collected between February 2015 and November 2016, 
of 1564 adults of mixed-ancestry, who participated in the 
Cape Town Vascular and Metabolic Health study. Kidney 
function was estimated using the Modification of Diet 
in Renal Disease (MDRD) and Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equations. CKD 
was defined as estimated glomerular filtration rate (eGFR) 
<60 mL/min/1.73 m2, and anaemia as haemoglobin level 
<13.5 g/dL (men) and <12 g/dL (women).
results Based on the MDRD and CKD-EPI equations, the 
crude prevalence of CKD was 6% and 3%. Irrespective 
of the equation used, median red blood cell (RBC) indices 
were consistently lower in those with CKD compared with 
those without CKD (all p<0.0001). Despite not showing 
any significant difference in total white blood cell (WBC) 
count between the two groups, the number of lymphocytes 
were lower (p=0.0001 and p<0.0001 for MDRD and CKD-
EPI, respectively) and neutrophil count (both p<0.0297) 
and the ratio of lymphocytes to neutrophil (both p<0.0001) 
higher in the CKD group compared with those without 
CKD; with the remaining WBC indices similar in the two 
groups. The platelet count was similar in both groups. 
Of the screen-detected CKD participants, 45.5% (MDRD) 
and 57.8% (CKD-EPI) were anaemic, with the prevalence 
increasing with increasing severity of CKD, from 37.2% 
(stage 3) to 82.4% (stages 4–5). Furthermore, CKD-EPI-
estimated kidney function, but not MDRD, was positively 
associated with RBC indices.
Conclusion Though it remains unclear whether common 
kidney function estimators provide accurate estimates 
of CKD in Africans, the correlation of their estimates 
with deteriorating RBC profile, suggests that advocated 
estimators, to some extent approximate kidney function in 
African populations.
bACkgrOund 
Chronic kidney disease (CKD) is a major 
global public health problem,1 estimated to 
affect more than 10% of the general adult 
population and up to 50% of some high-risk 
subpopulations, such as the elderly,2 those 
with non-communicable diseases (NCDs), 
including type 2 diabetes mellitus (T2D) and 
hypertension, and communicable diseases 
(CDs), including HIV/AIDS.3 4 Africa is 
currently experiencing the double burden 
of NCDs and CDs which are all driving the 
increasing burden of CKD on the continent.5 
However, the exact burden of CKD in Africa 
has yet to be fully elucidated,6–9 in part due 
to the absence of appropriate estimates for 
predicting reduced kidney function in indi-
viduals from African ancestry.9 10 
CKD encompasses a wide range of physio-
logical processes altered by the progressive 
decline in glomerular filtration rate (GFR).11 12 
Haematological parameters, particularly red 
blood cell (RBC) indices, are most commonly 
affected,13 giving rise to anaemia. Anaemia is 
the most common, consistent and severe of 
the various haematological abnormalities, 
strengths and limitations of the study
 ► The first study to characterise the haematological
profile of individuals with reduced kidney function
in a population-based setting in Africa, even more
specific, individuals of mixed-ancestry.
 ► We studied a community with a high burden of obe-
sity, hypertension and diabetes, reflective of the cur-
rent burden in Africa.
 ► This study was conducted in only one geographical
area which may not adequately reflect all the mixed
ancestry population groups in Sub-Saharan Africa.
 ► Our study was based on a single serum creati-
nine measure to determine chronic kidney disease
(CKD) and did not include estimates of albuminuria.
Albuminuria, which are required for clinical and aeti-
ological diagnosis of CKD, as this information is im-
portant particularly in the interpretation of estimated 
glomerular filtration rate (eGFR) greater that 60 mL/
min/1.73 m2 where inaccuracies of the eGFR equa-
tions are greatest.
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and has been shown to be a very common condition in 
black Africans.14 Although anaemia may be found at any 
stage of CKD, the severity of anaemia increases with CKD 
progression,15 resultantly affecting nearly all patients with 
end-stage renal disease (CKD stage 5).13 The predomi-
nant cause of anaemia in CKD is failure of the kidneys 
to produce enough endogenous erythropoietin, which 
accompanies the fall in GFR.16 17 Untreated, prolonged 
anaemia is strongly predictive of all-cause and cardio-
vascular mortality, as well as reduced quality of life and 
increased morbidity in patients with CKD.13 18 Untreated 
anaemia can also accelerate the decline in renal function 
by causing renal haemodynamic alterations and tissue 
hypoxia.15 Other potentially affected haematological 
parameters in CKD, of which the association with CKD 
is not yet fully characterised, include total and differen-
tial white blood cell (WBC) counts. Persistent, low-grade 
inflammation is an essential part of the aetiology of CKD 
and has been recognised as such since the late 1990s, when 
it was linked to cardiovascular disease and mortality.19 
Recently, the ratio of neutrophil-to-lymphocyte count 
(N/L) has been proposed as a novel measure of inflam-
mation in distinct populations and has been shown to 
have prognostic value20; particularly for mortality risk in 
patients with myocardial infarction and heart failure.21 22 
However, studies on the relationship of N/L ratio with 
reduced estimated GFR (eGFR) are limited.23 Thus, 
despite recent advances in the aetiology governing the 
development and progression of CKD, population-based 
data on the haematological profile of people with CKD in 
Africa are scanty.
We therefore aimed to characterise the haematological 
profile of screen-detected CKD participants in a commu-
nity-based sample, and to correlate the complete blood 
count measures with two commonly advocated kidney 
function estimators of CKD in urban South Africans of 
mixed-ancestry.
MethOds
study setting and population
The current study used data from the ongoing Cape 
Town Vascular and Metabolic Health study, an extension 
of the Cape Town Bellville-South study, which has been 
described in detail previously.24 Bellville-South, with a 
population of approximately 29 301, is a township formed 
in the late 1950s, located in the metropolitan city of Cape 
Town, South Africa. The population consists predom-
inantly of individuals of mixed-ancestry (coloured) 
(76%), followed by black Africans (18.5%), with only 
1.5% of the population being of Caucasian and Asian 
ancestry. The data collection for the current analysis took 
place between February 2015 and November 2016 during 
a community-based survey involving only mixed-ancestry 
South Africans. 
Participant involvement
The participants were not involved in the design or 
recruitment process of this study. However, permission to 
conduct the study was obtained from relevant authorities 
including the city and community authorities.
Questionnaires and physical examination
All interviews and physical examinations took place at a 
research clinic on the campus of Cape Peninsula Univer-
sity of Technology, located within the study suburb. All 
consenting participants received a standardised inter-
view, explained in great detail elsewhere.25 Physical 
examination involved blood pressure (BP) determina-
tion, measured according to the WHO guidelines,26 
using a semiautomatic digital BP monitor (Omron M6 
comfort-preformed cuff BP Monitor), placed on the 
right arm in sitting position and at rest for at least 10 min. 
Three measures were taken of which the average of the 
lowest two was used in all analyses. Body weight (to the 
nearest 0.1 kg) was measured with the participant in light 
clothing and without shoes, using an Omron body fat 
meter HBF-511 digital bathroom scale which was cali-
brated and standardised using a weight of known mass. 
Height (to the nearest centimetre) was measured with a 
stadiometer, with subjects standing on a flat surface. Body 
mass index (BMI) was calculated as body weight per body 
height squared (kg/m2). Waist circumference (WC) was 
measured with a non-elastic tape measure at the level of 
the narrowest part of the torso, as seen from the anterior 
view. Anthropometric measurements were performed 
three times and the average used for analysis.
biochemical analysis and calculations
All biochemical analyses took place at an ISO 15189 
accredited Pathology practice (Path-Care, Reference 
Laboratory, Cape Town, South Africa). Blood samples 
were collected from all participants after an overnight 
fast, and 2 hours after a 75 g oral glucose tolerance test 
(OGTT) following the WHO recommendations.27 Plasma 
glucose levels and haemoglobin A1c (HbA1c) were 
measured by enzymatic hexokinase method (Beckman 
AU, Beckman Coulter, South Africa) and high perfor-
mance liquid chromatography (Biorad Variant Turbo, 
BioRad, South Africa), respectively. Insulin was deter-
mined by a paramagnetic particle chemiluminescence 
assay (Beckman DXI, Beckman Coulter, South Africa). 
Triglycerides (TG), total cholesterol (TC), and high-den-
sity lipoproteins (HDL-C) were analysed using the Roche 
Modular auto analyser and enzymatic colorimetric assays, 
and low-density lipoproteins (LDL-C) were calculated 
using the Friedewald formula.28 The homeostatic model 
assessment of insulin resistance (HOMA-IR) was calcu-
lated according to the formula: HOMA-IR = [fasting 
insulin concentration (mIU/l)×fasting plasma glucose 
(mmol/l)/22.5. Serum concentration of high sensi-
tivity C-reactive protein (hsCRP) (Immun Diagnostik 
AG, Bensheim, Germany) was analysed using commer-
cially available ELISA kits according to the manufactur-
er’s protocols. Serum creatinine was measured by the 
modified Jaffe-Kinetic method (Beckman AU, Beckman 
Coulter, South Africa). Creatinine assays at our Partner 
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pathology service are standardised to the internationally 
accepted reference method (isotope dilution mass spec-
trophotometry) since 2009 and eGFR estimators appli-
cable to standardised creatinine values were used. Kidney 
function was assessed using serum creatinine-based 
eGFR, namely, the 4-variable Modification of Diet in 
Renal Disease (MDRD) equation29 and the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) 
equation30. The African-American ethnicity correction 
factor was omitted from the eGFR calculation, as the 
South African Renal Society CKD guidelines promote the 
exclusion of the correction factor, except in the case of 
black Africans. Full blood counts, including total RBC, 
total WBC, lymphocytes count and percentage, monocyte 
count and percentage, neutrophil count and percentage, 
basophil count and percentage, eosinophil count and 
percentage, haemoglobin, haematocrit, mean corpus-
cular volume (MCV), mean corpuscular haemoglobin 
(MCH), MCH concentration (MCHC), red cell distri-
bution width (RDW) and platelets were measured on a 
Coulter LH 750 haematology analyser (Beckman Coulter, 
South Africa).
Classification of renal function and comorbidities
Staging of kidney function was based on the National 
Kidney Foundation Disease Outcomes Quality Initia-
tive classification.31 An eGFR <60 mL/min/1.73 m2 was 
used to define CKD (or CKD stage 3–5). Anaemia was 
defined using the National Kidney Foundation Kidney 
Disease Outcome Quality Initiative (K/DOQI) guide-
lines (haemoglobin level <13.5 g/dL for men and <12 g/
dL for women)32 and further classified into microcytic, 
normocytic and macrocytic based on the MCV. Microcytic 
anaemia was defined as an MCV of <80 fL, normocytic 
as 100–80 fL and macrocytic as >100 fL.33 Hypertension 
was based on either a history of diagnosed hypertension 
(receiving medications for hypertension) or screen-de-
tected hypertension. The latter being classified if they 
had a systolic BP (SBP) ≥140 mm Hg and/or diastolic BP 
≥90 mm Hg.34 Diabetes status was based on a history of
diagnosed diabetes or screen-detected diabetes. OGTT
glucose values were used to classify the glucose toler-
ance status of participants as recommended by WHO35
as: (1) normal glucose tolerance (fasting plasma glucose
(FPG) <6.1 mmol/L and 2-hour glucose <7.8 mmol/L);
(2) pre-diabetes including impaired fasting glycaemia
(IFG, 6.1≤FPG<7.0 mmol/L), impaired glucose tolerance
(IGT, 7.8<2-hour glucose <11.1 mmol/L) and the combi-
nation of both; and (3) diabetes (FPG ≥7.0 mmol/L and/
or 2-hour glucose ≥11.1 mmol/L). BMI ≥25 kg/m2 and
BMI ≥30 kg/m2 were classified as overweight and obese,
respectively.
statistical analysis
All statistical analyses were performed using STATA V.13 
(Statcorp), and statistical significance was based on a p 
value <0.05. General characteristics of the participants 
are summarised as count and percentage for qualitative 
variables and median and 25th–75th percentiles for 
quantitative variables. Group comparisons used χ2 test 
for qualitative variables, and Wilcoxon rank-sum test for 
quantitative variables, respectively. Multiple linear regres-
sion models were used to assess the independent associ-
ation between eGFR and haematological indices, while 
adjusting for age and gender.
results
Participant characteristics
The initial study sample comprised 1647 participants. Of 
those, 83 were excluded due to missing data on serum 
creatinine or any of the variables required to estimate 
kidney function, including age and gender. The general 
characteristics and the haematological profile of the study 
population are summarised in tables 1 and 2, respectively. 
The final sample included 1564 participants, of which 
24.9% were male, with a group median age of 50 years. 
The crude prevalence of CKD was 6% and 3%, based on 
the MDRD and CKD-EPI equations, respectively. Of those 
participants with MDRD-diagnosed CKD, 80.7%, 14.8% 
and 4.5% where in stages 3, 4 and 5, respectively. Similarly, 
of those diagnosed by means of the CKD-EPI equation, 
68.9%, 24.4% and 6.7% where in stages 3, 4 and 5, respec-
tively. MDRD-diagnosed CKD participants had higher 
creatinine levels (111.5 vs 59 µmol/L; p<0.0001) and lower 
eGFR (48.2 vs 104 mL/min/1.73 m2; p<0.0001), were on 
average older (68 vs 49 years; p<0.0001), with a higher 
WC (97.7 vs 91.2 cm; p=0.0001), BMI (30.3 vs 28.3 kg/
m2; p=0.0096), and SBP (142 vs 125 mm Hg; p<0.0001), 
compared with participants with normal kidney func-
tion. Furthermore, MDRD-diagnosed CKD participants 
had higher fasting and 2-hour blood glucose (5.3 vs 
5.0 mmol/L; p<0.0001 and 7.2 vs 6.0 mmol/L; p<0.0001, 
respectively), HbA1c levels (6.2 vs 5.7%; p<0.0001), 
fasting and 2-hour insulin levels (8.4 vs 6.7 IU/L; 
p=0.0089 and 62.0 vs 37.5 IU/L; p=0.0002, respectively), 
higher HOMA-IR index (2.1 vs 1.6; p=0.0004), hsCRP 
(4.7 vs 4.0 µg/mL; p=0.0492), TG (1.6 vs 1.2 mmol/L; 
p<0.0001) and TC (5.4 vs 5.1 mmol/L; p=0.024); with 
similar LDL-C (3.2 vs 3.1 mmol/L; p=0.0668) and HDL-C 
levels (1.3 vs 1.3 mmol/L; p=0.7106) compared with those 
without CKD. When subdividing the groups based on 
CKD diagnosed by the CKD-EPI equation, similar differ-
ences were observed, with the exception of BMI, hsCRP 
and TC which showed no difference between the groups 
(28.3 vs 28.4 kg/m2; p=0.384, 4.8 vs 4.0 µg/mL; p=0.4268, 
5.3 vs 5.1 mmol/L; p=0.2226, respectively). Participants 
with reduced kidney function, both MDRD and CKD-EPI 
diagnosed, had a similar prevalence of overweight and 
obesity, however had a higher prevalence of hypertension 
and T2D, despite similar prevalence of pre-diabetes (IFG 
and IGT) between the two groups.
The RBC indices, including RBC count, haematocrit 
and haemoglobin levels were consistently lower in CKD 
participants compared with the group with normal kidney 
function (all p<0.0001), irrespective of the eGFR equation 
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used. Conversely, the morphology of the RBCs were not 
different, as similar values for MCV, MCH, MCHC and 
RDW were observed between CKD participants and the 
participants with normal kidney function. Despite not 
showing any significant difference in total WBC count 
between the two groups, the number of lymphocytes were 
lower and neutrophil count and the ratio of lymphocytes 
to neutrophil higher in the CKD group compared with 
those individuals with normal kidney function; with the 
remaining WBC indices similar in the two groups. The 
platelet count was similar in both groups. Furthermore, 
based on the K/DOQI guidelines, 45.5% (MDRD) and 
57.8% (CKD-EPI) of the CKD participants had anaemia, 
with the majority of cases being normocytic. Moreover, 
the prevalence of anaemia increased with increasing 
severity of CKD, from 37.2% at stage 3% to 82.4% at stage 
4–5.
Association between the different haematological indices and 
egFr
The age and gender-adjusted associations between the 
different haematological indices and eGFR, estimated 
by means of the MDRD and CKD-EPI equations, are 
presented in table 3. Based on the CKD-EPI, however 
not the MDRD equation, eGFR was positively associated 
with all the RBC indices, including total RBC count, 
haemoglobin and haematocrit levels. eGFR was not asso-
ciated with total WBC count, however a lower lympho-
cyte count was associated with a lower eGFR, and N/L 
ratio was inversely associated with eGFR. Furthermore, 
male gender was significantly associated with all haema-
tological measures, except basophil count and eosino-
phil count, and age was inversely associated with all RBC 
indices, lymphocytes, neutrophils, platelet count, MCHC 
and positively associated with RDW.
disCussiOn
In this community-based sample of mixed-ancestry South 
Africans, we have shown that the haematological profile 
of individuals with reduced eGFR (<60 mL/min/1.73 m2) 
are substantially impaired compared with those with 
normal kidney function, giving rise to the high preva-
lence of anaemia in this screen-detected CKD population. 
Furthermore, despite eGFR being positively associated 
with RBC indices, indicative of the severity of kidney 
function impairment, the disease state had no effect on 
the morphology of the RBC. Lastly, we confirmed that a 
chronic proinflammatory state exists in participants with 
CKD.
This study, which is in accordance with other studies 
in Africa and other low-income and middle-income 
countries,36–42 has shown that CKD is associated with 
significant impairment in RBC indices. Indeed, we have 
shown that total RBC count, haemoglobin concentration 
and percentage haematocrit were substantially reduced 
in participants with eGFR below 60 mL/min/1.73 m2, 
compared with those with normal kidney function, V
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independent of age and gender. Since erythropoietin is 
produced mainly by the proximal tubule of the nephron, 
kidney function decline will result in a decline in eryth-
ropoietin production and as a consequence result in 
decreased haemoglobin synthesis, leading to a fall in 
total RBC count.17 This significant reduction in RBC, 
inevitably gives rise to anaemia.14 Indeed, our study and 
numerous other studies have shown that the severity of 
anaemia increases with disease progression; with most 
of these studies showing anaemia at least twice as preva-
lent in participants with CKD, compared with the general 
adult population.37 Furthermore, we found that 17% of 
the sample population with normal kidney function had 
haemoglobin levels <13.5 g/dL and <12 g/dL for men 
and women, respectively. However, this is not uncommon 
in Africa as previous studies have found that Africa has 
a high prevalence of anaemia caused by iron deficiency. 
In South Africa in particular, the South African National 
Health and Nutrition Examination Survey43 showed that 
22% and 12.2% of adult females and males have anaemia.
The activation of the immune system, caused by inflam-
mation, increases WBC counts23; emphasising the poten-
tial of WBC indices as a surrogate marker of inflammation 
in CKD.20 Our study showed that despite no correlation 
between total WBC and reduced kidney function, CKD 
was associated with higher neutrophil and lower lympho-
cyte counts; both of which are independently associ-
ated with the promotion of atherosclerosis44 45 and poor 
cardiovascular outcomes.46 N/L ratio, which combines 
the predictive power of both increased neutrophil 
count and decreased lymphocyte count,47 was associated 
with reduced eGFR in our study, as also found in other 
studies.23 48 49 Indeed previous studies, which included 
patients with CKD on haemodialysis23 48 and predialysis,49 
showed that an increased N/L ratio was associated with 
known inflammatory markers such as tumour necrosis 
factor-α,23 interleukin 6 and hsCRP levels.49 These studies 
demonstrated that these well-established markers of 
inflammation were independent factors for predicting 
N/L ratio, thus presenting N/L ratio as an inflammatory 
biomarker for patients with CKD. Since full blood count 
analysis are done routinely, and a relatively affordable 
and easy measure to acquire, these findings are espe-
cially valuable taking into account the severely resource 
limited setting found in Africa and other low-income and 
middle-income countries.
Our study has a few limitations. This study was 
conducted in only one geographical area which may 
not adequately reflect all the mixed ancestry population 
groups in Sub-Saharan Africa. Furthermore, this was a 
community-based sample with high female to male partic-
ipation, however the latter being a common trend in 
South African population studies. Our study also used a 
single serum creatinine measure to determine the grade 
of kidney function and did not include estimates of albu-
minuria. Albuminuria, in particular, is required for clin-
ical and aetiological diagnosis of CKD, as this information 
is important particularly in the interpretation of eGFR 
greater that 60 mL/min/1.73 m2 where inaccuracies of 
the eGFR equations are greatest. It is however a common 
practice in community-based studies to diagnose CKD 
using a single measurement of serum creatinine. Further-
more, we did not investigate other haematinic deficien-
cies, such as vitamin B12 and iron deficiencies which, if 
present however, are less likely to affect haematological 
profile in a differential way in people with and without 
CKD. However, despite these limitations, we are not 
aware of other studies that have assessed the haematolog-
ical profile of individuals with reduced kidney function in 
a population-based setting in Africa, even more specific, 
individuals of mixed-ancestry. Furthermore, we studied a 
community with a high burden of obesity, hypertension 
and diabetes, reflective of the current burden in Africa. 
This study provides much needed evidence for the asso-
ciation between the haematological profile and CKD as 
population-based data on the haematological profile of 
people with CKD in Africa are very limited.
In conclusion, the findings from our study are valu-
able as full blood count analyses are done routinely and 
are relatively affordable, taking into account the severely 
resource-limited setting found in Africa and other low-in-
come and middle-income countries. Furthermore, though 
it still remains unclear whether the advocated kidney 
function estimators provide accurate estimates of CKD 
burden in African populations,49 the correlation of these 
estimates, with deteriorating profile of blood cell counts, 
suggests that these advocated GFR estimates, particularly 
the CKD-EPI equation, to some extent, measure kidney 
function in African populations.
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